TrialThe oncologist2019

Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.

Jae-Joon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.